Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer

NCT02046421 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02046421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02046421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
May 31, 2018
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

male breast cancer, recurrent breast cancer, recurrent fallopian tube cancer, recurrent ovarian epithelial cancer, recurrent primary peritoneal cavity cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer